Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) CEO Aras Azadian

Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) CEO Aras Azadian – RICH TV LIVE – February 12, 2021 – Avicanna Inc. (“ Avicanna ” or the “ Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that the Company has entered into an intellectual property licensing and royalty agreement with Harrington Wellness Inc. (“ Harrington Wellness” ) for the commercialization of a CBD topical product line targeting athletes and active consumers in Canada and the U.S. (the “ re+PLAY Agreement ”).

Hi guys how you doing i am your host rich here and we have a rich tv live with our very special guest araz as a zadian the ceo of avicanna how are you doing today araz doing well how are you i’m doing fantastic thank you for joining us today excited to have you on the show and i wanted to start off by asking you why don’t you tell us a little bit about avicanna

And what made you want to become the ceo sure so i’m the founding ceo so i think it started with me wanting to create the company then to be the ceo i had two co-founders we walked we came from different walks of life one was a patient advocate looking at cannabinoids as medicine and the other one said to period who’s the president was a an attorney with a

Fun understanding of the regulations we started the company 2015 with the vision of providing standardized medicine using cannabinoids my background prior to that i was in the biotech sector i was a management consultant i was an executive and a couple of biotech companies i learned how how you know a biotech a biopharma company functions and when i saw the

Cannabis opportunity i realized that you know all the companies that were there the initial let’s say the big four five were really predominantly focused on cultivation and you know weed where i knew that the ultimately standardized medicine data evidence to educate physicians and to provide patients with the right methods and right products is going to be the

Massive market opportunity and we started with that vision and considering my qualifications as a biotech executive the three of us decided that it would make the most amount of sense for me to to be the ceo and i basically took the huge leap of faith and we incepted the company together now you mentioned this a little bit what are the main focuses of avicanna

Inc for the first half of 2021 and some of the milestones the company has already set to achieve so when we started off in 2015 the idea was to take a traditional drug development process so your gw pharma you know drug development optimization pre-clinical clinical development and we did that you know we were part of a johnson and johnson incubator we’re

The only cannabis company that has ever been admitted to that so we’re inside jnj’s research center we have our own cannabis research places it’s all pharma and you know but about two years into it where we started developing these more advanced drugs tablets capsules transdermal patches and topicals we realize that the drug development clinical development

Pathway which we are we’re taking and we’re still doing is is a long journey but our expertise which is really advanced cannabinoid standardized medicine actually has faster root to market channels which is medical cannabis cosmetics so we started developing more products for today’s market and and we are today in 2021 we have our medical line commercial and

The largest pharmacy chain in canada shoppers drug mart we’re selling them in latin america in colombia we have our cosmetic line commercial in a couple countries and our pharmaceutical drugs which where we started off from are actually progressing and or they’re being registered in many countries as well so really we’re a recently commercialized biotech

See also  10 things I tell people Starting a Business or thinking about Entrepreneurship!

Biopharma company that has specialized in cannabinoid-based medicine and we’ve established what we believe is the most strong or the most comprehensive scientific platform related to cannabinoid-based medicine in the world today wow that’s impressive you guys are doing some incredible things and only the first time we got a chance to meet and i haven’t heard

Much about your company yet so i’m very excited about learning more and having our entire community really start sinking their teeth in and learning more about your company now the cannabis space is starting to really pick up and now that the possible legalization in america is coming can you tell us what sets avican inc apart from the rest so so we’re we’re

A biotech biopharma company that works with cannabinoids we’re not a cannabis company so i don’t sell joints i don’t sell pre-rolls i’m not a multi-state operator we trade on the tsx as a biotech company not as not as the cannabis company so the opportunity that that is opening up to the united states is i believe a lot bigger than what people actually perceive

So if you’re a multi-state operator that means you can cross borders and get access to capital and you can sell more joints and pre-rolls and stuff like that great opportunity and i’m completely fond of that and i believe in that but that’s a recreational company for the medical the biotech the pharma companies the advancements in the united states means better

Access to capital means more sophisticated investors that believe in biotech and biopharma benefits of cannabinoids and gw pharma got acquired last week for eight billion dollars i mean the timing is great yeah this also means that big pharma is going to get a little bit more comfortable in getting involved with cannabis companies that are doing the biotech

And biopharma stuff right so i think for companies like us that have spent five years establishing a scientific platform have demonstrated our ability to take concept develop it in a lab optimize it do this clinical studies then commercialize it companies like us that have demonstrated that now become targets for funds institutions pharmaceutical companies

That are seeking to enter the space and because in canada is federally legal and we have the federal licenses to do these this research we believe we’re in the forefront of that we are the intellectual property that big pharma will start to look for to collaborate with or to acquire so i think the opportunity towards legalization or decriminalization in the

United states has benefits for the multi-state operators but also has substantial benefits for the biotech biopharma companies very exciting i like what you guys are doing it’s very unique and you guys are focused on the medicinal side you guys are focused on the research side on on you’re not focused like you said on joints i don’t like that you’re not

Touching the plant correct we actually are vertically integrated in colombia so i’m cultivating organic sustainable low cost but all of that input material gets processed into what we call apis active pharmaceutical ingredients cbd cbg thc and then that goes into our finished drugs so we don’t sell flour but we do have vertical integration and we’ve built

That in a developing country in an organic sustainable way so that we can maintain the quality and the cost that we need to supply the rest of the world the entire world is pretty excited about the benefits of cannabis from a medicinal perspective and i think as investors as an investment community we are often distracted by recreational use or adult use

See also  8 Tiny Changes That Make You Seem More Competent

Which is predominantly can in the united states but outside of that adult use and recreational is not legal anywhere else there’s uruguay but that’s a very small country so really the big ter big time global opportunity for advanced medicine with cannabinoids is it really a global opportunity right and that’s what we focus on so colombia gives us access to

Low enough cost input material so that when i have a bottle of capsules or tablets or topical that has cannabinoids we’re talking 10 20 30 products not hundreds of dollars of product so yes we are vertically integrated but still it’s focused on medicine and an evidence-based approach now it’s vital when our community is looking at investing in stocks and in

Companies like yours that are early stage undervalued under appreciated underexposed opportunities that we get a good chance to understand who’s behind the team so can you tell me a little bit about the team at avicanna and what the key members bring to the table absolutely i think one of the most unique things about this team is that it’s the same executive

Team from the beginning so i’m a biotech executive we have lawyers clinicians r d scientists there’s overall about 10 full-time employees that are mds or phds in this company and we’re a very relatively small company so this is a very professional centric science-centric company and it’s the same core team so setu is a co-founder he’s an attorney our head

Of r d france he’s developed a lot of the formulations and the technologies we’re using where carolina is leading our medical and clinical programs our head of marketing yvonne has been with us and from the beginning blue class leads our operations in south america he’s argentinian he’s been there from the beginning so the team is the same core team from

The beginning all professionals and what’s remarkable is how tightly held not only has the team been but our shares we’ve only issued 30 something million shares it’s all been strategic partners which include some large pharmaceutical companies including costly pharma in china and some important funds in brazil states um none of the management i’ve ever sold

Shares ever and i think that’s very important that we do believe in what we’ve established we’re starting to see more and more uh credibility amongst the the medical community in canada but also amongst the cannabis community globally that we are the intellectual property company so i think we’re all very proud of what we’ve accomplished and it’s because the

Team has really stayed true to that vision of evidence-based cannabis medicine and stay together along the pathway now you mentioned your share structure that is vital for our community we love tight float stocks can you break down your share structure how much is held by insiders and institutions i think about 40 is still held by the management and board which

Is really important the three co-founders probably still about owned probably about 30 again we haven’t been very dilutive and then there’s there’s several institutions some canadian funds a couple of brazilian funds um costly pharma in china like there’s a couple of big pharma shareholders uh i think if i was to estimate i would say 75 80 of the company is

Very tightly held wow so it’s a very tight flow and you mentioned you’ve never sold a single share since you’ve been involved in the company myself the the rest of the senior team never obviously have to disclose as we do so it’s it’s online anyone can see it we really believe in what we built um we believe we’re substantially undervalued because until as of

Recently people didn’t really know the value of biotech pharma everyone thought cannabis is just joints you know and now more and more evidence is coming we are proving that as well we have you know clinical collaborations with the most important hospitals and academic institutions in canada we’ve had that for years so finally we’re starting to get a little

See also  What Does Wealth Buy If Not Happiness

Bit of credit for that where three four years ago everyone would always ask me why are you doing all this research why are you doing that why don’t you just grow weed and sell it and that’s that’s not what we do you know our our effort and our time was spent in putting out more advanced medicine what’s exciting for me and my shareholders today is that we

Are not commercial so as for a biotech company to become commercial it’s a lot more complicated it’s a longer path than for a company that grows weed puts in a bag and sells it and the fact that we are not commercial means we’ve passed very important milestones from a regulatory perspective and we’re commercial in several countries so it’s it’s a very very

Exciting time for us if there was one thing you would want shareholders to know about avicana what would it be um we’re dedicated to setting the standards for what medical cannabis or medicine from the source of cannabinoids is meant to be at a global level and we have done our homework we’ve stayed committed to that we stayed true to that and they will see

The results of that at a global level in a very very short period of time and what is the best way for shareholders to get in contact with you we’re going to have this video shown all over the world to investors that are watching within our community in about 100 countries what would be the best way for them to reach you or the company if they’re interested

In making an investment maybe a joint venture partner maybe an loi someone has some interest what’s the best way for them to reach you the pg-13 way is of course info abby canada.com or ir avicanna dot com you can find me on linkedin my team is trying to convince me to get twitter because i’m apparently very opinionated and people want to hear that so for

Now linkedin is the easiest way to reach me okay great well thank you so much for your time today araz azadian the ceo of avicanna super excited to have you on the show today guys remember rich tv live is strictly for education and entertainment purposes always do your due diligence always do your research before you invest in anything that we talk about here

In rich tv live consult a financial advisor chances are if you consult a financial advisor about avicana they’re going to say hmm that’s a really nice pick i really like what i see about this company guys symbol in canada a v c n symbol in america a v c n f and symbol in frankfurt germany o n n if you’re not winning you’re not watching we bring in the winners

And we bring them to you first put this pick on your radar put on your watch list if you like the video smash the like button comment down below share the video everywhere and subscribe all right araz thank you so much for your time today keep up the great work and i hope to have you on the show again one time in the future thank you thanks for having me keep

Up the great work and we’ll be watching thank you for watching everybody have a nice day

Transcribed from video
Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) CEO Aras Azadian By RICH TV LIVE

Scroll to top